The Alpha Variant (B.1.1.7) of SARS-CoV-2 Failed to Become Dominant in Mexico.
Alpha
Mexico
SARS-CoV-2
genomic surveillance
Journal
Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614
Informations de publication
Date de publication:
27 04 2022
27 04 2022
Historique:
pubmed:
8
4
2022
medline:
30
4
2022
entrez:
7
4
2022
Statut:
ppublish
Résumé
During the coronavirus disease 2019 (COVID-19) pandemic, the emergence and rapid increase of the B.1.1.7 (Alpha) lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first identified in the United Kingdom in September 2020, was well documented in different areas of the world and became a global public health concern because of its increased transmissibility. The B.1.1.7 lineage was first detected in Mexico during December 2020, showing a slow progressive increase in its circulation frequency, which reached its maximum in May 2021 but never became predominant. In this work, we analyzed the patterns of diversity and distribution of this lineage in Mexico using phylogenetic and haplotype network analyses. Despite the reported increase in transmissibility of the B.1.1.7 lineage, in most Mexican states, it did not displace cocirculating lineages, such as B.1.1.519, which dominated the country from February to May 2021. Our results show that the states with the highest prevalence of B.1.1.7 were those at the Mexico-U.S. border. An apparent pattern of dispersion of this lineage from the northern states of Mexico toward the center or the southeast was observed in the largest transmission chains, indicating possible independent introduction events from the United States. However, other entry points cannot be excluded, as shown by multiple introduction events. Local transmission led to a few successful haplotypes with a localized distribution and specific mutations indicating sustained community transmission.
Identifiants
pubmed: 35389245
doi: 10.1128/spectrum.02240-21
pmc: PMC9045257
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0224021Références
Mol Biol Evol. 2022 Feb 3;39(2):
pubmed: 35038741
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
Nature. 2021 Mar;591(7849):293-299
pubmed: 33494095
Euro Surveill. 2021 Mar;26(10):
pubmed: 33706862
Syst Biol. 2016 Jan;65(1):82-97
pubmed: 26424727
J Virol. 2020 Aug 31;94(18):
pubmed: 32641486
BMJ. 2021 Mar 9;372:n579
pubmed: 33687922
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Science. 2021 May 21;372(6544):815-821
pubmed: 33853970
Mol Biol Evol. 2020 May 1;37(5):1530-1534
pubmed: 32011700
Cell. 2021 May 13;184(10):2595-2604.e13
pubmed: 33891875
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
Viruses. 2021 Oct 26;13(11):
pubmed: 34834967
Cell. 2020 Sep 3;182(5):1295-1310.e20
pubmed: 32841599
Nature. 2021 May;593(7858):270-274
pubmed: 33723411
Cell. 2021 Aug 5;184(16):4220-4236.e13
pubmed: 34242578
Arch Virol. 2021 Nov;166(11):3173-3177
pubmed: 34448936
Mol Biol Evol. 2020 Feb 1;37(2):599-603
pubmed: 31633786
Cell. 2021 May 13;184(10):2587-2594.e7
pubmed: 33861950
Viruses. 2021 Apr 29;13(5):
pubmed: 33946747
mBio. 2022 Apr 26;13(2):e0009922
pubmed: 35266815
Nature. 2021 Apr;592(7853):277-282
pubmed: 33545711
Wellcome Open Res. 2021 May 19;6:121
pubmed: 34095513
Lancet Infect Dis. 2021 Nov;21(11):1507-1517
pubmed: 34171231
Nat Methods. 2017 Jun;14(6):587-589
pubmed: 28481363
Genome Biol. 2019 Jan 8;20(1):8
pubmed: 30621750